Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03388619 · ClinicalTrials.gov registry record · Phase 1
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03388619: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT03388619 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03388619, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Background: Sometimes prostate cancer comes back after a person's prostate is removed. In this case, radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective. It is usually given in short doses almost every day for 6 or 7 weeks. Researchers want to see if a shorter schedule can be as effective. They want to see if that causes the same or fewer side effects. Usually, radiation is used to treat the entire area where the prostate was before surgery. In some patients, an area of tumor can be seen on scans. Researchers are also trying to see if they can give less dose to the area usually treated with radiation if the full dose is given to the tumor seen on scans. Objective: To find the shortest radiation schedule that people can tolerate without strong side effects. Eligibility: People at least 18 years old who have had a prostatectomy and will get radiation. Design: Participants will be screened with: * Medical history * Physical exam * Blood and urine tests * Scan that uses a small amount of radiation to make a picture of the body * Scan that uses a magnetic field to make an image of the body * Participants will provide documents that confirm their diagnosis. * Participants may have a scan of the abdomen and pelvis. Before they start treatment, participants will have another physical exam and blood tests. Participants will get radiation each day Monday through Friday. Treatment may last 2, 3, or 4 weeks. Participants may provide a tissue sample from a previous procedure for research. Participants will answer questions about their general well-being and function. About 4-5 weeks after they finish radiation treatment, participants will have a follow-up visit. They will be examined and give a blood sample. They will have 6 follow-up visits for the next 2 years.
Interventions
- DIAGNOSTIC_TEST CT
- RADIATION Prostate bed with integrated boost
- RADIATION Prostate bed irradiation only
- DIAGNOSTIC_TEST Whole Body Bone Scan
- DIAGNOSTIC_TEST 18F-NaF PET Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2025-12-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03388619
The ClinicalTrials.gov registry entry for NCT03388619 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which CT is the first listed.
NCT03388619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03388619 about?
NCT03388619 is a clinical study titled "Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy". Background: Sometimes prostate cancer comes back after a person's prostate is removed. In this case, radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective. It is usually given in short doses almost every day for 6 or 7 weeks. Researchers want to see if a s...
What is the current status of trial NCT03388619?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-01-17. Estimated completion is 2025-12-04.
What interventions are being tested in trial NCT03388619?
The interventions under investigation include: CT (DIAGNOSTIC_TEST), Prostate bed with integrated boost (RADIATION), Prostate bed irradiation only (RADIATION), Whole Body Bone Scan (DIAGNOSTIC_TEST), 18F-NaF PET Imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03388619?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.